COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.

In an article previously published in I Cancer i , Cattaneo et al1 analyzed a cohort of patients with coronavirus disease 2019 (COVID-19) and hematological malignancies in March 2020, and they highlighted that subjects with chronic myeloid leukemia (CML) had a lower than expected frequency of COVID-19. COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. [Extracted from the article]